XSTO
CEVI
Market cap496mUSD
Jun 09, Last price
199.60SEK
1D
2.89%
1Q
20.97%
Jan 2017
132.09%
IPO
1,471.65%
Name
CellaVision AB
Chart & Performance
Profile
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 723,217 6.78% | 677,292 5.94% | 639,340 13.05% | |||||||
Cost of revenue | 545,539 | 510,240 | 481,074 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 177,678 | 167,052 | 158,266 | |||||||
NOPBT Margin | 24.57% | 24.66% | 24.75% | |||||||
Operating Taxes | 36,138 | 33,913 | 30,094 | |||||||
Tax Rate | 20.34% | 20.30% | 19.01% | |||||||
NOPAT | 141,540 | 133,139 | 128,172 | |||||||
Net income | 140,722 7.99% | 130,309 10.12% | 118,335 -5.59% | |||||||
Dividends | (53,666) | (53,666) | (47,703) | |||||||
Dividend yield | 1.03% | 1.06% | 0.87% | |||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 14,171 | 36,039 | 42,131 | |||||||
Long-term debt | 12,678 | 59,611 | 98,249 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 6,254 | 4,945 | 3,739 | |||||||
Net debt | (122,581) | (30,391) | 26,987 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 198,438 | 196,436 | 137,285 | |||||||
CAPEX | (77,749) | (31,769) | (69,434) | |||||||
Cash from investing activities | (76,006) | (85,532) | (70,014) | |||||||
Cash from financing activities | (95,089) | (97,036) | (90,410) | |||||||
FCF | 150,139 | 134,318 | 61,076 | |||||||
Balance | ||||||||||
Cash | 149,430 | 121,645 | 108,053 | |||||||
Long term investments | 4,396 | 5,340 | ||||||||
Excess cash | 113,269 | 92,176 | 81,426 | |||||||
Stockholders' equity | 705,589 | 630,828 | ||||||||
Invested Capital | 848,829 | 693,861 | 666,378 | |||||||
ROIC | 18.35% | 19.58% | 20.95% | |||||||
ROCE | 19.35% | 19.76% | 19.77% | |||||||
EV | ||||||||||
Common stock shares outstanding | 23,852 | 23,852 | 23,852 | |||||||
Price | 217.50 2.59% | 212.00 -7.42% | 229.00 -29.58% | |||||||
Market cap | 5,187,711 2.59% | 5,056,624 -7.42% | 5,462,108 -29.58% | |||||||
EV | 5,065,130 | 5,026,233 | 5,489,095 | |||||||
EBITDA | 177,678 | 206,815 | 198,363 | |||||||
EV/EBITDA | 28.51 | 24.30 | 27.67 | |||||||
Interest | 8,159 | 3,260 | 2,340 | |||||||
Interest/NOPBT | 4.59% | 1.95% | 1.48% |